Thuleau Aurélie - Inst Curie, Paris, France

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 44 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Figure 1 from Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma

Jordan Madic,Sophie Piperno-Neumann,Vincent Servois,Aurore Rampanou,Maud Milder,Bénédicte Trouiller,David Gentien,Stéphanie Saada,Franck Assayag,Aurélie Thuleau,Fariba Nemati,Didier Decaudin,François-Clément Bidard, Laurence Desjardins,Pascale Mariani,Olivier Lantz, Marc-Henri Stern

openalex（2023）

Cited0Views0Bibtex

Table S1. Top Upregulated and Downregulated Canonical Pathways and Genes Following Treatment with AZD5363. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) in Vivo

Ricardo Ribas,Sunil Pancholi,Stephanie K. Guest,Elisabetta Marangoni,Qiong Gao,Aurélie Thuleau,Nikiana Simigdala,Urszula M. Polanska,Hayley Campbell,Aradhana Rani,Gianmaria Liccardi,Stephen Johnston, Barry R. Davies,Mitch Dowsett,Lesley-Ann Martin

openalex（2023）

Cited0Views0Bibtex

S2. Formal Assessment of AZD5363 Combination Indices in Response to the Addition of Various Endocrine Agents. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) in Vivo

openalex（2023）

Cited0Views0Bibtex

S1. Antiproliferative effect of escalating doses of AZD5363 in endocrine sensitive and resistant cell lines {plus minus} estrogen or androstenedione. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo

openalex（2023）

Cited0Views0Bibtex

S4. Effect of AZD5363 on the Expression of Endogenous ER Genes by Qrt-Pcr. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) in Vivo

openalex（2023）

Cited0Views0Bibtex

S3. Temporal Effect of the Combination of AZD5363 with Endocrine Therapy on PI3K/mTOR/AKT, ER and Cell Cycle Signalling. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) in Vivo

Ricardo Ribas,Sunil Pancholi,Stephanie K. Guest,Elisabetta Marangoni, Qiong Gao,Aurélie Thuleau,Nikiana Simigdala,Urszula M. Polanska,Hayley Campbell,Aradhana Rani,Gianmaria Liccardi,Stephen Johnston, Barry R. Davies,Mitch Dowsett, Lesley-Ann Martin

openalex（2023）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn